SCHEMBL2484641

SCHEMBL2484641

CC(C)Oc1ccc([C@H]2CC[C@H](O)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 3/20 0.53
TSHR P16473 1/20 0.50
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
KCNH2 Q12809 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
POLB P06746 3/20 0.44
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PTGDR Q13258 1/20 0.39
ALDH1A3 P47895 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.38
IDO1 P14902 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2484638 1.00 ESR2 (0.53) ESR2TSHRCYP3A4CYP2C9KCNH2
SCHEMBL14446350 0.83 TSHR (0.54) TSHRKCNH2HRH3POLBKMT2A
SCHEMBL8629643 0.82 TSHR (0.50) ESR2TSHRPOLBKMT2ANPC1
SCHEMBL8629644 0.82 TSHR (0.50) ESR2TSHRPOLBKMT2ANPC1
SCHEMBL8629646 0.82 TSHR (0.50) ESR2TSHRPOLBKMT2ANPC1
SCHEMBL2453970 0.81 ESR2 (0.49) ESR2CYP3A4CYP2C9KCNH2HRH3
SCHEMBL2778901 0.81 ESR2 (0.49) ESR2CYP3A4CYP2C9KCNH2HRH3
SCHEMBL1506423 0.79 ESR2 (0.59) ESR2CYP3A4CYP2C9KCNH2HRH3
SCHEMBL1506578 0.79 ESR2 (0.59) ESR2CYP3A4CYP2C9KCNH2HRH3
SCHEMBL1506422 0.79 ESR2 (0.59) ESR2CYP3A4CYP2C9KCNH2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364088-B1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC INC (US) 2014-04-16 EP disclosed
US-8546359-B2 Bicyclic aryl sphingosine 1-phosphate analogs BIOGEN IDEC MA INC. (US) 2013-10-01 US disclosed
US-20130059821-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN MA INC. 2013-03-07 US disclosed
US-8269043-B2 Bicyclic aryl sphingosine 1-phosphate analogs BIOGEN IDEC MA INC. (US) 2012-09-18 US disclosed
EP-2364088-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS Biogen Idec MA Inc. (US) 2011-09-14 EP disclosed
US-20100160258-A1 Bicyclic aryl sphingosine 1-phosphate analogs BIOGEN IDEC MA INC. (US) 2010-06-24 US disclosed
WO-2010051030-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC MA INC. (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160258-A1 Bicyclic aryl sphingosine 1-phosphate analogs S1PR1, S1PR3, S1PR4 ESR2 1507/4885TSHR 452/4885CYP3A4 3570/4885
US-20130059821-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS S1PR1, S1PR2, S1PR3 ESR2 1360/4885TSHR 206/4885CYP3A4 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.